BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/20/2024 8:50:41 AM | Browse: 207 | Download: 625
 |
Received |
|
2024-07-21 08:27 |
|
Peer-Review Started |
|
2024-07-21 08:27 |
|
First Decision by Editorial Office Director |
|
2024-08-05 21:08 |
|
Return for Revision |
|
2024-08-05 21:08 |
|
Revised |
|
2024-08-24 07:32 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-09-06 03:03 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-09-06 05:58 |
|
Articles in Press |
|
2024-09-06 05:58 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-09-12 17:00 |
|
Publish the Manuscript Online |
|
2024-09-20 08:50 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Dual-targeted treatment for inflammatory bowel disease: Whether fecal microbiota transplantation can be an important part of it
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Zi-Ning Zhang and Li-Xuan Sang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The Science and Technology Plan of Liaoning Province, China |
No. 2022JH2/101500063 |
|
| Corresponding Author |
Li-Xuan Sang, MD, PhD, Professor, Department of Gastroenterology, The Shengjing Hospital of China Medical University, No. 39 Gliding Road, Tiexi District, Shenyang 110022, Liaoning Province, China. sanglixuan2008@163.com |
| Key Words |
Gut microbiota; Inflammatory bowel disease; Fecal microbiota transplantation; Dual-targeted treatment; Combination treatment |
| Core Tip |
The combination of biologic agents or the combination of a biologic agent and a novel small-molecule drug for treating inflammatory bowel disease (IBD) carries certain risks, and some patients are resistant to these drugs. The regulation of the gut microbiota has become a potential treatment for IBD, and the inclusion of fecal bacteria transplantation in dual-targeted treatments for IBD holds great promise. |
| Publish Date |
2024-09-20 08:50 |
| Citation |
Zhang ZN, Sang LX. Dual-targeted treatment for inflammatory bowel disease: Whether fecal microbiota transplantation can be an important part of it. World J Gastroenterol 2024; 30(36): 4025-4030 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i36/4025.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i36.4025 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
